Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

NCT01791465 on ClinicalTrials.gov · last registry update 2017-03-10

Stopped early, having planned 6 participants. The sponsor logged completion for December 2014. Primary outcome, as filed: Serum Highly-sensitive C-reactive Protein (hsCRP) Levels at Baseline and 16 Weeks. exenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Vanderbilt University
Sponsor type: Other
Enrollment: 6
Started: 2013-03
Primary completion: 2014-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Serum Highly-sensitive C-reactive Protein (hsCRP) Levels at Baseline and 16 Weeks

Conditions studied

Human Immunodeficiency Virus Infection · Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.